

Monthly DRUP Study Newsletter #76, 01 July 2022

The Drug Rediscovery Protocol (DRUP Trial):

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile

It is time to take a break...



Highlights:

To date more than 1200 patients have started a DRUP treatment

Study Update

To date, a total of 2292 cases have been submitted to the study team and 1067 of these have started a treatment within the DRUP stage 1 and 2 cohorts and 142 within the closed DRUP stage 3 nivolumab for MSI tumors cohort.

The DRUP drug arsenal currently includes 34 different drugs, divided over a total of 281 cohorts. For a complete overview please visit our website at www.drupstudy.nl and log in to the protected area. The login details can be requested via drup@nki.nl. Information about open cohorts will no longer be posted in the monthly newsletter. Furthermore, the website also includes an overview in the form of a map showing where all the 35 participating DRUP hospitals are to be found.

Information to all participating sites

We would kindly like to remind all participating sites to **always perform cerebral imaging at baseline for patients known to have brain metastases**. All disease must be recorded at baseline and not longer than 28 days before start treatment.

Event & meetings

On 17th of June we arranged a sponsor meeting in the NKI. The study team enjoyed meeting some of the very motivated Stelvio for life participants and having the opportunity to share with them what the DRUP study really is about and why their support is so important to us and the continuity of the study. On 3rd of September we will be there to cheer them on while climbing Passo dello Stelvio for a good cause. We wish them the best of luck!

Because of upcoming holidays the next newsletter will be issued in September, but in the meantime;

The DRUP study team would like to wish you all a fantastic summer!

Warm regards,

Principal Investigators: Henk Verheul, Hans Gelderblom, Emile Voest
Study Coordinators: Laurien Zeverijn, Gijs de Wit, Birgit Geurts, Ilse Spiekman
Clinical Project Manager: Lena Bilet

Table 1: List of pharmaceutical companies & study drugs

Confidential, list might be subjected to change

Currently available

<u>Amgen</u> Panitumumab	<u>Eisai</u> Lenvatinib	<u>Bayer</u> Regorafenib	<u>Roche</u> Erlotinib Trastuzumab+ Pertuzumab
<u>BMS</u> Nivolumab Ipilimumab	<u>AstraZeneca</u> Olaparib Durvalumab	<u>Clovis Oncology</u> Rucaparib	Vemurafenib+ Cobimetinib Vismodegib
<u>Novartis</u> Dabrafenib Nilotinib Trametinib Ribociclib Alpelisib	<u>Pfizer</u> Axitinib Crizotinib Sunitinib Palbociclib Talazoparib, dacomitinib Lorlatinib	<u>MSD</u> Pembrolizumab	Atezolizumab+ bevacizumab Alectinib Entrectinib
	<u>Lilly</u> Abemaciclib	<u>BI</u> Afatinib	<u>Janssen</u> Erdafitinib

Committed


<u>Lilly</u> Selpercatinib	<u>GSK</u> Niraparib	<u>Merck</u> Tepotinib
-------------------------------	-------------------------	---------------------------

Calendar & publicity

September, 3rd Stelvio for Life

Table 2: Submission and accrual overview

July 1st, 2022



Submissions and accrual 3rd stage cohort Nivolumab for MSI tumors

July 1st, 2022

